UNH
UnitedHealth Group Inc. · Minnesota, USA · Est. 1974
⚠ DOJ Investigation · CEO Change · MCR Crisis
$282.63
All-time High $630.73  ·  Down 55% from peak
M/Cap $256.3B
P/E 14.73 · Ind. 16.15
BQ 18 / 30
Segments UHC · Optum Health · Insight · Rx
MCR Q3 89.9%
2026 Rev Guide +2%
Verdict
UNH is America's largest health insurer — but 2025 was a year of compounding disasters. Medical Cost Ratio surged to 89.9%, Optum Health margins collapsed from 8.3% to near-zero, the CEO was shot and replaced, a DOJ investigation is ongoing, and EPS guidance was cut four times from $29.50 to $14.90. The company expects recovery by 2027 — but that's a long wait with high execution risk. At PEG 0.80, it looks statistically cheap. But this is a show-me story that needs MCR stabilisation, DOJ resolution, and Optum Health recovery before conviction is warranted.
Medical Cost Ratio — The Core Problem
—
Q3 2025 MCR  ·  Historical target ~83–85%
80% (ideal)85% (target)90% (danger)
Business Quality Score
RG
3
GM
3
OC
3
OM
3
NI
3
FCF
3
18 / 30  ·  All average — reflecting a company in reset
Analyst Consensus · 28 Analysts
$280
Low
$391
Avg
$444
High
Current $282.63 — just above analyst floor of $280
20
Buy / Outperform
8
Hold / Underperform
Earnings Surprise / EPS Guidance Cuts
MISSQ1
MISSQ2
BEATQ3
BEATQ4
RG Est  +1.88% FY2026  ·  +4.95% FY2027
EPS Guidance Collapse — 2025
Dec 2024 Guidance $29.50 – $30.00
After Q1 $26.00 – $26.50
After Q2 ≥ $16.00
After Q3 (Final) ≥ $16.25 adj.
Guidance cut by ~46% over the year. Q4 EPS down 69% YoY.
Revenue Breakdown by Segment
SegmentFY2024 MixYoYQ2 2025 MixYoYFY2025 MixYoY
Total Revenue—+8%—+13%—+12%
UnitedHealthcare54%+6%56%+6%56%+16%
Optum (total)46%+12%44%+7%44%+7%
— Optum Health42%+11%37%−7%38%−3%
— Optum Rx53%+15%56%+19%57%+16%
— Optum Insight7%−1%7%+6%7%+4%
Premiums (rev type)77%+6%79%+14%79%—
Optum Health revenue declined despite volume — driven by higher medical costs on underpriced risk contracts. Optum Rx (+19% Q2) remains the bright spot.
Operating Margin Collapse
UNH Group Operating Margin
8.1% FY244.6% Q22.7% FY25
Optum Health Margin
7.4% FY241.0% Q3~0.1% Q4
Net Earnings Margin
5.4% FY243.1% Q22.2% Q3
Valuation vs. 12 Peers
P/E
14.77
#4 / 12
Fwd P/E
13.60
#4 / 12
PEG
0.80
#2 / 12
P/S
0.59
#8 / 12
P/FCF
14.76
#6 / 12
ROIC
10.46%
#2 / 12
Dividend
3.24%
#2 / 12
Debt/Eq
0.78x
#7 / 12
⚠ Critical — Structural Integrity Under Review

Three independent issues — V28 model losses, CEO assassination, and DOJ investigation — converged in 2025. Each alone would be manageable. Together they represent the most significant crisis in UNH's history.

Key Events — click to expand
MCR CrisisMedical Cost Ratio hit 89.9% — structural or cyclical?
▼
MCR surged from ~85% historical to 89.9% in Q3 2025. The V28 CMS risk model transition alone costs ~$11B over three years according to analyst estimates. Optum Health assumed full risk on underpriced Medicare Advantage contracts — and got burned when utilisation spiked post-COVID. UnitedHealthcare is dropping 100+ Medicare Advantage plans in 2026, affecting 600,000 members, as it pulls back from unprofitable markets.
DOJDOJ investigation ongoing — scope and outcome unclear
▼
A DOJ investigation is underway. Former CEO Brian Thompson was shot in December 2024 — Stephen Hemsley returned as Chairman and CEO. The combination of leadership instability and regulatory investigation creates significant overhang. The company also faces disclosure concerns: $3.3B in asset sale gains were counted as operating income in 2024, which critics argue inflated reported profitability.
OptumOptum charges UHC 2x market rates — internal conflict flagged
▼
Analysts flagged that Optum is charging UnitedHealthcare twice the market rate for services — inflating Optum's reported margins while artificially pressuring UHC margins. This cross-segment pricing dynamic makes it difficult to assess true segment profitability and raises questions about disclosure quality. Poor transparency is a recurring theme in analyst coverage.
MedicareCMS rate increase only 0.09% vs projected 4–6%
▼
CMS proposed Medicare rates that were essentially flat (+0.09%), while the industry had modelled 4–6% increases to offset utilisation trends. This rate shortfall compounds the MCR crisis — the company is caught between higher costs and lower reimbursement simultaneously. Management expects Medicare margins to decline further in 2026 if rates and cost trends don't change.
RecoveryCEO guiding double-digit growth from 2027 — VBC expansion
▼
Stephen Hemsley (CEO) explicitly guided double-digit earnings growth from 2027. Value-Based Care expansion is expected to grow at 17.4% CAGR. Medicaid stabilisation is expected by 2026. 78% of plans are rated 4-star or higher for 2026 (vs 75% in 2025), improving Medicare reimbursement eligibility. The recovery thesis exists — but it requires flawless execution across multiple fronts simultaneously.
Key Risks
MCR Does Not StabiliseIf medical cost trends continue into 2026, margins will fall further. Each 100bps of MCR = $1B+ earnings impact at current scale.
DOJ Investigation EscalatesOutcome unknown, timeline unclear. Settlement costs and reputation damage could be significant.
Optum Health ImpairmentV28 transition alone = $11B over 3 years. VBC membership shrinking 10% in 2026. Recovery to 2027 is management's promise — not a market consensus.
Debt Load$32B cash against $79.19B total debt. Leverage limits flexibility at the worst possible time.
Upside Catalysts
2027 Recovery on TrackIf CEO's double-digit growth guidance proves accurate, the stock at current levels is deeply undervalued. PEG of 0.80 supports this thesis.
Medicaid StabilisationMedicaid margins expected to stabilise by 2026. Peer Molina already operating at 3% margin in the same space.
Star Rating Improvement78% of plans 4-star+ in 2026 vs 75% in 2025 — qualifies for higher CMS bonuses and improves Medicare economics.
VBC Long-Term TailwindValue-Based Care at 17.4% CAGR is a genuine structural growth driver if operational execution improves.
Conviction Level
LOW
Too many unresolved unknowns
Bull vs. Bear
BULL
  • ✓ PEG 0.80 — deeply cheap if 2027 growth lands
  • ✓ Double-digit growth guided for 2027
  • ✓ Optum Rx growing 15–19% consistently
  • ✓ Star ratings improving — better CMS rates
  • ✓ Largest US insurer — too big to structurally fail
BEAR
  • ✗ DOJ investigation — unknown severity
  • ✗ MCR still trending wrong direction
  • ✗ Optum Health breakeven at best in 2026
  • ✗ $79B debt with limited cash buffer
  • ✗ 2027 recovery requires simultaneous fixes
Recovery Signals to Watch
Critical Date
Q1 2026 Earnings — April 2026
First data point on whether MCR is stabilising below 89%
SIGNAL 1
MCR returns
below 87%
SIGNAL 2
DOJ investigation
resolved
SIGNAL 3
Optum Health margin
above 5%
SIGNAL 4
CMS 2027 rate
increase above 4%
Bottom Line

UNH is not a business in terminal decline — it is the largest US health insurer, and Optum Rx continues to grow at 15–19%. But 2025 was a year of simultaneous compounding failures: MCR at historic highs, Optum Health near breakeven, CEO change, DOJ investigation, and four guidance cuts. The stock has already fallen 55% from its peak, and PEG 0.80 looks superficially cheap.

The problem is that the 2027 recovery thesis requires too many things to go right at once — MCR stabilisation, Medicaid normalisation, Optum Health restructuring, CMS rate improvement, and DOJ resolution. Each has a reasonable probability. All five simultaneously is a high bar. Low conviction. Wait for Q1 2026 MCR data. The entry point will still be attractive if the numbers show stabilisation.